Halozyme Therapeutics, Inc. (0J2O.L)
USD 48.78
(0.12%)
USD 48.78
(0.12%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 388.57 Million | 240.11 Million | 299.44 Million | 55.45 Million | -85.42 Million | -49.5 Million |
| Net Income | 281.59 Million | 202.12 Million | 402.71 Million | 129.08 Million | -72.24 Million | -80.33 Million |
| Depreciation & Amortization | 84.85 Million | 49.64 Million | 2.99 Million | 3.28 Million | 4.06 Million | 2.38 Million |
| Deferred income taxes | 34.5 Million | 40 Million | -155.43 Million | 644 Thousand | 490 Thousand | -3.08 Million |
| Stock-based compensation | 36.62 Million | 24.39 Million | 20.82 Million | 17.2 Million | 34.77 Million | 35.69 Million |
| Change in working capital | -38.67 Million | -85.95 Million | 3.73 Million | -108.36 Million | -50.53 Million | -5.86 Million |
| Other non-cash items | -10.33 Million | 9.88 Million | 24.6 Million | 13.6 Million | -1.97 Million | 1.69 Million |
| Investing Cash Flow | -96.9 Million | -487 Million | -406.28 Million | 78.35 Million | -5.54 Million | 2.49 Million |
| Investments in PPE | -15.29 Million | -4.81 Million | -1.45 Million | -2.5 Million | -4.04 Million | -4.66 Million |
| Acquisitions | 81.61 Million | -999.12 Million | 404.83 Million | 1.07 Million | 1.5 Million | - |
| Investment purchases | -292.91 Million | -255.2 Million | -652.51 Million | -226.18 Million | -389.75 Million | -311.11 Million |
| Sales/Maturities of investments | 211.29 Million | 746.12 Million | 247.68 Million | 305.96 Million | 388.25 Million | 318.26 Million |
| Other Investing Activities | -81.61 Million | 26 Million | -404.83 Million | 80.85 Million | -1.5 Million | 7.15 Million |
| Financing Cash Flow | -407.98 Million | 362.37 Million | 77.86 Million | -106.28 Million | 153.21 Million | -63.79 Million |
| Debt repayment | -13.48 Million | -447.45 Million | -369.06 Million | -19.56 Million | -108.08 Million | -77.51 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -402.38 Million | -200 Million | -350.05 Million | -150.11 Million | -199.99 Million | - |
| Common Stock Issuance | 7.87 Million | 14.05 Million | 12.53 Million | 63.39 Million | 14.22 Million | 13.71 Million |
| Other Financing Activities | 7.87 Million | 995.77 Million | 796.98 Million | 63.39 Million | 461.29 Million | 13.71 Million |
| Accounts receivables | -3.33 Million | -83.94 Million | 6.75 Million | -38.28 Million | -29.43 Million | 11.61 Million |
| Accounts payables | -12.54 Million | 24.53 Million | 1.16 Million | -41.2 Million | 4.63 Million | -278.48 Million |
| Inventory | -26.88 Million | -17.48 Million | 7.37 Million | -31.38 Million | -6.73 Million | -17.48 Million |
| Other working capital | 4.09 Million | -9.06 Million | -11.55 Million | 2.51 Million | -19 Million | 278.48 Million |
| Cash at beginning of period | 234.69 Million | 119.21 Million | 148.2 Million | 120.67 Million | 58.43 Million | 169.24 Million |
| Cash at end of period | 118.37 Million | 234.69 Million | 119.21 Million | 148.2 Million | 120.67 Million | 58.43 Million |
| Capital Expenditure | -15.29 Million | -4.81 Million | -1.45 Million | -2.5 Million | -4.04 Million | -4.66 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -116.32 Million | 115.47 Million | -28.98 Million | 27.52 Million | 62.24 Million | -110.8 Million |
| Free Cash Flow | 373.27 Million | 235.3 Million | 297.98 Million | 52.95 Million | -89.46 Million | -54.16 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 137.01 Million | 93.24 Million | 76.82 Million | 281.59 Million | 85.38 Million | 81.83 Million |
| Depreciation & Amortization | 20.32 Million | 20.36 Million | 20.2 Million | 84.85 Million | 20.69 Million | 23.07 Million |
| Deferred income taxes | 292 Thousand | 14.24 Million | 1.29 Million | 34.5 Million | 9.42 Million | 9.7 Million |
| Stock-based compensation | 12.57 Million | 9.47 Million | 9.87 Million | 36.62 Million | 9.66 Million | 9.36 Million |
| Change in working capital | 60.7 Million | -82.26 Million | 21.55 Million | -38.67 Million | -26.09 Million | 22.08 Million |
| Other non-cash items | -115.54 Million | 90.95 Million | 51.88 Million | -10.33 Million | 3.28 Million | -13.66 Million |
| Investing Cash Flow | -167.48 Million | -42.03 Million | -82.68 Million | -96.9 Million | -8.29 Million | -83.45 Million |
| Investments in PPE | -1.51 Million | -2.58 Million | -3.54 Million | -15.29 Million | -2.59 Million | -2.94 Million |
| Acquisitions | - | - | - | 81.61 Million | 5.69 Million | 80.5 Million |
| Investment purchases | -303.97 Million | -93.42 Million | -198.76 Million | -292.91 Million | -21.29 Million | -161.69 Million |
| Sales/Maturities of investments | 138 Million | 53.96 Million | 119.62 Million | 211.29 Million | 15.59 Million | 81.19 Million |
| Other Investing Activities | - | -39.45 Million | -79.13 Million | -81.61 Million | -5.69 Million | -80.5 Million |
| Financing Cash Flow | 18.56 Million | 9.48 Million | -489 Thousand | -407.98 Million | -249.92 Million | 4.1 Million |
| Debt repayment | - | - | - | -13.48 Million | -13.48 Million | - |
| Dividends payments | - | - | - | - | -13.48 Million | - |
| Common Stock Repurchased | 489 Thousand | - | -489 Thousand | -402.38 Million | -252.3 Million | - |
| Common Stock Issuance | 19.05 Million | 8.99 Million | -489 Thousand | 7.87 Million | 2.38 Million | 4.1 Million |
| Other Financing Activities | -978 Thousand | 489 Thousand | -489 Thousand | 7.87 Million | 2.38 Million | 4.1 Million |
| Accounts receivables | -71.22 Million | -18.62 Million | 38.3 Million | -3.33 Million | -16.88 Million | 28.85 Million |
| Accounts payables | -21.87 Million | - | 18.68 Million | -12.54 Million | 11.46 Million | - |
| Inventory | 1.98 Million | -21.4 Million | -40.23 Million | -26.88 Million | 1.46 Million | 3.63 Million |
| Other working capital | 18.75 Million | -42.23 Million | 23.48 Million | 4.09 Million | -22.14 Million | -10.4 Million |
| Cash at beginning of period | 187.86 Million | 164.62 Million | 118.37 Million | 234.69 Million | 274.22 Million | 221.16 Million |
| Cash at end of period | 154.31 Million | 187.86 Million | 164.62 Million | 118.37 Million | 118.37 Million | 274.22 Million |
| Capital Expenditure | -1.51 Million | -2.58 Million | -3.54 Million | -15.29 Million | -2.59 Million | -2.94 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -33.54 Million | 23.23 Million | 46.25 Million | -116.32 Million | -155.85 Million | 53.06 Million |
| Free Cash Flow | 113.85 Million | 53.21 Million | 125.88 Million | 373.27 Million | 99.75 Million | 129.46 Million |
AHEXY
AZTR
603156
ALEFRM
605218
SSCFF